Funding for this research was provided by:
National Institute on Aging (RF AG051504, R01 AG061796, U01 AG046139)
National Institute of Neurological Disorders and Stroke (R01 NS080820, R01 NS078086)
Received: 24 September 2020
Accepted: 2 October 2020
First Online: 22 October 2020
Compliance with ethical standards
: This study was approved by the Institutional Review Board at Mayo Clinic. All participants or next-of-kin provided consent.
: Not applicable.
: RCP consults for Roche, Inc., Merck, Inc., Genentech, Inc., and Biogen, Inc., GE Healthcare, and receives royalties from Oxford University Press for the publication of Mild Cognitive Impairment. NRG-R has served on the editorial board of Alzheimer Disease and Therapy; has received publishing royalties from UpToDate; and has received research support from TauRx, Lilly, Biogen, and NIA. ZKW is partially supported by the Mayo Clinic Center for Regenerative Medicine, the gifts from The Sol Goldman Charitable Trust, and the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson’s Research Foundation. He serves as PI or Co-PI on Biogen, Inc. (228PD201) grant, and Biohaven Pharmaceuticals, Inc. (BHV4157-206 and BHV3241-301) grants. The remaining authors declare that they have no competing interests.